Overview

Radcliffe Cardiology is proud to announce a new one-day event New Horizons in Amyloidosis (NHA), specially focused on providing an update on the diagnosis and treatment of cardiac amyloidosis and its sequelae in recognition of this rapidly developing field.  

Hosted on www.radcliffecardiology.com, the event will be streamed on Wednesday 28 February 2024. This programme is designed to educate healthcare professionals on the evolving management practices in cardiac amyloidosis and is tailored to update and educate a variety of professionals including cardiologists, imaging specialists, electrophysiologists, primary care physicians, hematologists, and cardiac nurse practitioners.

This event, led by Course Director Dr Rodney Falk (Brigham and Women’s Hospital in Boston, US), will feature a distinguished group of faculty members who are renowned experts in the field of cardiac amyloidosis. The faculty will encompass a diverse range of medical specialties, facilitating a comprehensive, multidisciplinary approach.

Register now - We look forward to welcoming you to this first-time event.

*New Horizons in Amyloidosis’s programme will be submitted for accreditation to the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 4 CME points, equating to 4 hours of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

Event starts in:

Share this event:

Programme

(Please note this programme is subject to change)

2:00 PM - 2:05 PM (GMT)

Event Welcome

Welcome and Introduction



2:05 PM - 3:00 PM (GMT)
Plenary Session
Session 1: Detect, Screen and Diagnose

  • General diagnosis overview
  • When to suspect cardiac amyloidosis
  • Screening algorithms and decision support tools


3:00 PM - 3:45 PM (GMT)
Breakout
The Next Frontier in Amyloidosis Management: Comprehensive CMR Imaging Strategies for Improved Patient Outcomes

Learning Objectives

  • Determine the value of cardiac MRI for evaluating cardiac amyloidosis.

  • Identify CMR features consistent with amyloidosis.

  • Recall patient characteristics suggestive of amyloidosis and warrant assessment with CMR.

 



This breakout is sponsored by Circle Cardiovascular Imaging.


3:45 PM - 5:05 PM (GMT)
Plenary Session
Session 2: Detect, Screen and Diagnose

  • Imaging masterclass 1 Assessing structure and function: Transthoracic echo with case example

  • Imaging masterclass 2 Tissue characterisation: MRI with case example

  • Imaging masterclass 3 Definitive diagnosis: Optimal techniques for scintigraphy

  • Genotype and genetic testing

 



5:05 PM - 5:30 PM (GMT)
Plenary Session
Setting up a Multidisciplinary Amyloidosis Centre: The Neurologist Perspective

5:30 PM - 6:30 PM (GMT)
Plenary Session
Session 3: Management of CA and its Sequelae

  • Management of AL cardiomyopathy: The importance of a haematology cardiology interaction
  • ATTR management: TTR stabilisers and silencers
  • Future disease modifying therapy for ATTR


6:30 PM - 7:30 PM (GMT)
IME Symposium
ATTR-CM: Where Are We Now and Where to Next?

Agenda

  • Welcome and Introduction

  • Presentation: Measuring Success in ATTR-CM: Now and in the Future

  • Presentation: Is reversal within reach?

  • Audience questions and closing remarks

Learning Objectives

  • Recall what the current ATTR-CM therapy landscape is in terms of clinical efficacy

  • Quantify the current need to reverse CM disease in terms of progressive disease and mortality rate

  • Describe the process of antibody-mediated disease reversal

 



This IME symposium is supported by an unrestricted educational grant from AstraZeneca.


7:30 PM - 8:10 PM (GMT)
Plenary Session
Session 4: Management of CA and its Sequelae

  • HF & Arrhythmia management: AF, AV nodal disease, ventricular arrhythmias
  • Treatment success: Clinical and patient reported outcomes


8:10 PM - 8:15 PM (GMT)

Event Close

Closing remarks




Course Leadership

Rodney Falk

Rodney Falk
Course Director
Brigham and Women's Hospital, Boston, US

more info

Faculty

Timothy Albert
Timothy Albert
Circle Cardiovascular Imaging, Calgary, CA
Kevin Alexander
Kevin Alexander
Stanford University School of Medicine, Stanford, US
Sarah Cuddy
Sarah Cuddy
Brigham and Women's Hospital, Boston, US
Sharmila Dorbala
Sharmila Dorbala
Brigham and Women's Hospital, Boston, US
Marianna Fontana
Marianna Fontana
University College London, London, UK
Julian Gillmore
Julian Gillmore
University College London, London, UK
Finn Gustafsson
Finn Gustafsson
University of Copenhagen, Copenhagen DK
Philip Hawkins
Philip Hawkins
University College London, London, UK
Isabelle Lousada
Isabelle Lousada
Amyloidosis Research Consortium, Newton, US
Ana Martinez-Naharro
Ana Martinez-Naharro
Royal Free London NHS Foundation Trust, London, UK
Ahmed Masri
Ahmed Masri
Oregon Health & Science University Medical Group, Portland, USA
Kanae Mukai
Kanae Mukai
Salinas Valley Health, California, US
Laura Obici
Laura Obici
I.R.C.C.S. San Matteo Polyclinic, Pavia, IT
Sven Plein
Sven Plein
University of Leeds, Leeds, UK
Márcia Waddington-Cruz
Márcia Waddington-Cruz
Federal University of Rio de Janeiro, Rio de Janeiro, BR

Learning Objectives

  • Increase the awareness of at-risk patients

  • Improve understanding of screening procedures

  • Provide guidance on the use of imaging for cardiac amyloidosis diagnosis

  • Improve awareness on current and emerging treatment

  • Provide guidance on the management of key comorbidities

Target Audience

  • Cardiologists (device implanters, heart failure)

  • Imaging Specialists

  • Electrophysiologists

  • Primary care

  • Haematologists

  • Cardiac Nurse Practitioners

Educational Partners

Partner

If you're interested in becoming a partner at NHA, please contact sales@radcliffe-group.com

Official Journal

Cardiac Failure Review (CFR) is an international, English language, peer-reviewed journal that publishes articles continually to CFRjournal.com and aims to assist time-pressured physicians to stay abreast of key advances and opinion in the area ofheart failure. 

The journal comprises balanced and comprehensive review articles and original research written by leading authorities. The journal provides updates on a range of salient issues to support physicians in developing their knowledge and effectiveness in day-to-day clinical practice.

The journal endeavours to support the continuous medical education of specialist and general cardiologists and disseminate knowledge of the field to the wider cardiovascular community.

Partnership: CFR is the official journal of the Italian Heart Failure Association (ITAHFA).

Journal website: www.cfrjournal.com

CFR Journal

About Radcliffe Cardiology

We are Radcliffe, a knowledge network for the cardiovascular community

We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.

We bring medical knowledge to life

From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.

Our work is underpinned by 3 core principles:

  • We build on the best science
  • We work hands-on with our community
  • We bring fresh thinking


Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.

For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com